Clinical Trials Logo

Clinical Trial Summary

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02146430
Study type Interventional
Source Daiichi Sankyo, Inc.
Contact
Status Completed
Phase Phase 3
Start date October 27, 2014
Completion date July 14, 2016

See also
  Status Clinical Trial Phase
Completed NCT02187159 - Treatment of Pain Associated With Fibromyalgia Phase 3
Completed NCT02187471 - Treatment of Pain Associated With Fibromyalgia Phase 3
Completed NCT02234583 - An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia Phase 3
Completed NCT01773993 - Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)